Answers are grounded in this paper and cite their sources.
New classes of antithrombotic and fibrinolytic agents are highlighted as important therapies for reducing morbidity and mortality in acute coronary syndromes.
The primary goals of the medical management of acute coronary syndromes are to restore and to maintain coronary patency. Blood flow in totally occluded coronary arteries is restored by fibrinolysis with plasminogen activators. The ongoing thrombosis is controlled by inhibiting the coagulation cascade and platelet activity. The latter is of greater importance, as the formation of platelet‐rich thrombi is the main pathophysiological mechanism leading to acute coronary syndromes. Several new classes of agents for the management of acute coronary syndromes have recently been introduced, including fibrin specific plasminogen activators, direct thrombin inhibitors, low molecular weight heparins, and inhibitors of the platelet receptor glycoprotein (GP) IIb‐IIIa. Recent major trials indicate that the use of these new agents may lead to a significant decrease in morbidity and mortality in patients with acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
J. David Talley (1999) conducted a review in Acute Coronary Syndromes. Medical management (fibrin specific plasminogen activators, direct thrombin inhibitors, low molecular weight heparins, GP IIb-IIIa inhibitors) was evaluated on Morbidity and mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: